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Abstract: BACKGROUND AIMS: Eosinophilic esophagitis (EoE) most often affects young patients of
reproductive age, yet little is known about its effects during pregnancy. We examined the course of
EoE during pregnancy, outcomes of pregnancies, and patient concerns related to pregnancy and EoE.
METHODS: We sent a survey that queried demographic and disease-specific characteristics as well as
pregnancy-related topics to all 151 female patients treated at 2 EoE centers in Switzerland. We analyzed
cross-sectional survey data. RESULTS: Of 72 patients that returned the survey, we identified 20 patients
that had at least 1 pregnancy and analyzed the data on 34 pregnancies. During pregnancy, improvement
of dysphagia was reported in 56% (19/34) of all pregnancies, whereas deterioration was reported in
20% (7/34) of all pregnancies. After delivery, dysphagia returned to the pre-pregnancy level in 68%
(13/19) of all pregnancies for patients with improvement of dysphagia and 57% (4/7) of all pregnancies
for patients with deterioration of dysphagia during pregnancy. Esophagogastroduodenoscopy during
pregnancy was required in less than 10% (3/34) of all pregnancies. Pregnancy-related complications
occurred in 12% of pregnancies (4/34). The leading patient-reported concerns were fear of heritability
(40% of patients, 8/20) and concerns of that use of medication would harm the fetus (30% of patients,
6/20). CONCLUSIONS: Pregnancy affects the course of EoE, with improvement of symptoms reported
in most patients. Dysphagia returned to the pre-pregnancy level following delivery. EoE has likely no
negative effects on outcomes of pregnancies.
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Abstract:  42 
Background & Aims: Eosinophilic esophagitis (EoE) most often affects young patients of 43 
reproductive age, yet little is known about its effects during pregnancy. We examined the 44 
course of EoE during pregnancy, outcomes of pregnancies, and patient concerns related to 45 
pregnancy and EoE. 46 
 47 
Methods: We sent a survey that queried demographic and disease-specific characteristics as 48 
well as pregnancy-related topics to all 151 female patients treated at 2 EoE centers in 49 
Switzerland. We analyzed cross-sectional survey data. 50 
 51 
Results: Of 72 patients that returned the survey, we identified 20 patients that had at least 1 52 
pregnancy and analyzed the data on 34 pregnancies. During pregnancy, improvement of 53 
dysphagia was reported in 56% (19/34) of all pregnancies, whereas deterioration was reported 54 
in 20% (7/34) of all pregnancies. After delivery, dysphagia returned to the pre-pregnancy 55 
level in 68% (13/19) of all pregnancies for patients with improvement of dysphagia and 57% 56 
(4/7) of all pregnancies for patients with deterioration of dysphagia during pregnancy. 57 
Esophagogastroduodenoscopy during pregnancy was required in less than 10% (3/34) of all 58 
pregnancies. Pregnancy-related complications occurred in 12% of pregnancies (4/34). The 59 
leading patient-reported concerns were fear of heritability (40% of patients, 8/20) and 60 
concerns of that use of medication would harm the fetus (30% of patients, 6/20).  61 
 62 
Conclusions: Pregnancy affects the course of EoE, with improvement of symptoms reported 63 
in most patients. Dysphagia returned to the pre-pregnancy level following delivery. EoE has 64 
likely no negative effects on outcomes of pregnancies.  65 
 66 
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Introduction 69 
Eosinophilic Esophagitis (EoE) is a chronic immune-mediated disease of the esophagus 70 
characterized clinically by symptoms of esophageal dysfunction and histologically by an 71 
eosinophil predominant inflammation.1 Because the peak incidence of this disease is among 72 
those between 20 and 30 years of age, female patients are often diagnosed and live with this 73 
condition during their reproductive age.1 74 
     Since EoE has a Th2-type inflammatory pattern 2 and may be considered as “asthma or 75 
atopic dermatitis of the esophagus”, its disease course during pregnancy might follow the one-76 
third rule: disease ameliorates in a third of patients, disease deteriorates in a third of patients, 77 
and disease remain unchanged in a third of patients as in asthma3; or that the disease might 78 
deteriorate in the majority of patients as in atopic dermatitis.4 It is generally considered that 79 
these allergic and autoimmune diseases course alterations during pregnancy occur as a result of 80 
down-regulation of Th1 cells and the up-regulation of Th2 cells,5, 6 as high concentrations of 81 
Th1- and Th17-type cytokines may have deleterious effects on outcome of pregnancy.7, 8  82 
In general, patients with chronic diseases may have unique challenges and concerns during 83 
pregnancy.9 From EoE patients’ perspective, it is important to know whether this condition has 84 
any consequences for a planned pregnancy.  85 
     To date, the data on pregnancy in EoE are extremely limited, with a single case series of 86 
four pregnant women in EoE published by Burk et al.10 The aim of this study was three-fold: 87 
to investigate the clinical course of EoE during pregnancy, to analyze the outcome of the 88 
pregnancies in patients with EoE, and to explore the disease-specific concerns female EoE 89 
patients might have had before pregnancies.  90 
 6 
Methods 91 
We conducted a cross-sectional questionnaire-based study in all female EoE patients treated at 92 
EoE Clinics in Olten and Zurich, Switzerland. Diagnosis of EoE was established based on the 93 
following criteria: clinically, based on presence of symptoms of esophageal dysfunction and 94 
histologically, based on esophageal peak eosinophilia of ≥ 15 eosinophils per high-power field 95 
(eos/hpf) in at least one biopsy specimen of the esophagus.11 Other conditions leading to 96 
esophageal eosinophilia were excluded. We developed a German language-based survey that 97 
queries the number of pregnancies, pregnancy complications (premature birth, miscarriage, 98 
gestational diabetes, high blood pressure, or other complications), mode of delivery, EoE-99 
specific pregnancy-related concerns (fear of heritability, fear of harming the unborn due to 100 
medication use, fear of EoE negatively impacting the course of pregnancy, fear of EoE 101 
deterioration, or other concerns), the presence of EoE symptoms including dysphagia during 102 
pregnancy and following delivery as well as change in EoE symptom severity (improvement or 103 
deterioration) in percent (10-30%, 31-50%, 51-70%, 71-100%) following the delivery 104 
compared to symptom severity during pregnancy, any EoE-related complication during 105 
pregnancy, the need of esophagogastroduodenoscopy during pregnancy, and the medication use 106 
and dose during pregnancy. Demographic and disease-specific data, such as age at the time of 107 
study enrollment, age at first manifestation and diagnosis of EoE, concurrent allergic diseases, 108 
and history of bolus impaction were also collected. The survey was sent and returned by post.  109 
     All statistical analyses were performed using the GraphPad Prism 5.0 (GraphPad Software, 110 
Inc., Sand Diego, CA). Quantitative data distribution was analyzed using Normal-QQ-Plots. 111 
Results of quantitative data are presented either as median plus interquartile ranges (for data 112 
with non-Gaussian distribution) or mean ± SD and range (for normally distributed data). 113 
Categorical data were summarized as the percentage of the group total. For quantitative data, 114 
differences in distribution between two groups were evaluated using either the Wilcoxon-115 
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Mann-Whitney rank test (for data with non-Gaussian distribution) or the Student’s t-test (for 116 
normally-distributed data). For categorical outcomes, differences in observed frequencies 117 
between groups were compared using the chi-squared test, or using the exact Fisher test for 118 
groups with a small number of observations (n<20). 119 
     The study was approved by the local ethics committee (No. EKNZ 2015-388). 120 
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RESULTS 121 
One hundred and fifty one female patients are treated in EoE clinics in Olten and Zurich, 122 
Switzerland. These patients were invited to participate in this study and were send paper-based 123 
survey. Seventy-two patients (48%) returned the survey and were included in this study. Of 72 124 
enrolled patients, 20 patients had at least one pregnancy after EoE diagnosis. Six patients (30%) 125 
had one pregnancy, whereas 14 patients (70%) had two pregnancies (total of 34 pregnancies) 126 
(Figure 1). One patient was pregnant at the time of the survey completion. The demographic 127 
and disease-specific characteristics are shown in Table 1. 128 
     The course of the dysphagia during pregnancy and after delivery is shown in Figure 2. Most 129 
patients experienced improvement in dysphagia during their pregnancies (56%), a quarter of 130 
patients observed no change in dysphagia, and a fifth experienced worsening of dysphagia. In 131 
patients reporting an improvement of dysphagia, more than half experienced an improvement 132 
by 71-100%, whereas in patients with a deterioration, the majority had only a deterioration of 133 
less than 30%. 134 
     After delivery, the severity of dysphagia returned to the pre-pregnancy state in the majority 135 
of patients. The median duration of improvement or deterioration in dysphagia severity during 136 
pregnancy was 3.0 months (IQR 0) or 6.0 months (IQR 1 month), respectively. After pregnancy, 137 
an improvement in dysphagia severity occurred after a median of 3.1 month (IQR 3.8 month), 138 
whilst a deterioration in dysphagia severity occurred after a median of 2.0 month (IQR 5.8 139 
month). During pregnancy, three patients (9%) experienced EoE-related complications 140 
requiring esophagogastroduodenoscopy: bolus impactions (n=2), and herpes simplex 141 
esophagitis (n=1).  142 
     Pregnancy-specific characteristics are shown in Table 2. Complications occurred in four 143 
(12%) of the pregnancies including one miscarriage. At the time point of data analysis, one 144 
patient was still pregnant.  145 
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     In 14 pregnancies (41%), patients did not take any EoE-specific medications. Of the 146 
remaining pregnancies, swallowed topical corticosteroids (STC), proton-pump inhibitors (PPI), 147 
and elimination diet were used in 13 (39%), nine (26%), and two pregnancies (6%), 148 
respectively. The rate of EoE-related complications requiring esophagogastroduodenoscopy in 149 
patients treated with EoE-specific modalities (2/20, 10%) and that in patients that did not 150 
undergo treatment (1/14, 7.1%) did not appear to differ (P = ns). Furthermore, the rate of 151 
pregnancy-related complications in patients (who finished their pregnancy) treated with EoE-152 
specific therapies (1/20, 5.0%) and that in patients without treatment (3/13, 23.1%) did not 153 
appear to differ (P = ns). 154 
     The major concerns reported by patients with prior pregnancy were fear of child inheriting 155 
EoE (40%), and fear of harming the child due to EoE medication use (30%). Only a minority 156 
of patients were concerned about a negative effect of pregnancy on EoE course or vice versa. 157 
Half of the patients (50%) reported no concerns at all (Table 2). 158 
  159 
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DISCUSSION 160 
Eosinophilic esophagitis (EoE) has an increasing prevalence and frequently affects individuals 161 
of child-bearing age. Whilst the study on contribution of genetic and environmental factors to 162 
EoE heritability have recently been carried out,12 the studies on impact of a pregnancy on 163 
esophageal inflammation and clinical disease course as well as outcome of pregnancies in EoE 164 
patients are scarce. In this survey-based study, we describe the case series of 20 EoE patients 165 
that experienced 34 pregnancies. Our main findings are as follows: 1) more than half of the EoE 166 
patients experienced symptom improvement during pregnancy; 2) the rate of pregnancy-related 167 
complications was low; and 3) major concerns reported by patients were fear of child inheriting 168 
EoE and harming the unborn child due to EoE medication use.  169 
     Given that during pregnancy clinical worsening of several autoimmune diseases, such as 170 
asthma and atopic dermatitis, was demonstrated in several studies3, 4, we learned with interest 171 
that more than half of the patients (56%) reported a marked improvement in their dysphagia, 172 
whereas only a minority (20%) of patients experienced deterioration of dysphagia severity. Our 173 
data pave way for prospective studies closely examining the alterations in EoE course during 174 
pregnancy as well as mechanistic work aimed to explore whether the pregnancy results in 175 
changes in levels of expression of various cytokines compared to pre/post-pregnancy state. 176 
     Chronic inflammation might have a negative impact on the outcome of pregnancies, either 177 
as a consequence of the disease activity itself or due to side effects of the treatment. In EoE, the 178 
risks of an uncontrolled disease activity as well as side effects of corticosteroids and potential 179 
nutritional deficits in those adhering to dietary regimens are all grounds for concern for 180 
healthcare professionals taking care of EoE patients. This was not the major concern for our 181 
EoE patients, as only one of the twenty patients feared that EoE might negatively impact the 182 
course of pregnancy. Our data show that the course of the pregnancies and deliveries were 183 
uneventful in almost 90% of all cases. A miscarriage occurred in one patient (3%). Since the 184 
miscarriage rate in high-income countries is approximately 10% in young women, it appears 185 
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that the prevalence of miscarriage in EoE patients is similar to that observed in the general 186 
population. 13 In addition, the incidence of premature birth (3%) and the rate of placental 187 
abruption (3%) in our study population is similar to that in other northern European countries 188 
(premature birth is observed in approximately 5% of patients, whilst placental abruption is 189 
observed in approximately 1% of patients).14,15. In summary, we did not document a negative 190 
impact of the underlying EoE on the course and the outcome of the pregnancies. 191 
     Almost one third of patients had concerns that their medication could have a negative impact 192 
on the outcome of the pregnancy. The only approved medication for treatment of EoE are 193 
swallowed topical corticosteroids (STC), which have a favorable safety profile and represent 194 
the first-line treatment in non-pregnant patients.16,17,18 Topically-acting corticosteroids can be 195 
safely administered during pregnancy in patients with skin diseases and asthma.19,20 However, 196 
one must keep in mind that STC are metabolized differently depending on the mode of 197 
application. In our study, three pregnancy-related complications occurred in patients that did 198 
not undergo any treatment (3/13; 21.3%), and one complication (1/20; 5.0%) occurred in the 199 
group undergoing treatment. The one complication in a patient treated with STC was a herpes 200 
esophagitis. However, that was supposed to be unrelated to the medication and more a surrogate 201 
marker for an uncontrolled EoE. In summary, the rate of pregnancy-related complications was 202 
not higher in patients adhering an anti-inflammatory treatment with STC during pregnancy 203 
when compared to that in patients taking no medications for EoE management.  204 
     Mode of delivery is an important topic for expectant mothers regardless of whether they 205 
have a chronic disease or not. In Switzerland, caesarean section rate of 33% is one of the highest 206 
worldwide.14 Our analysis demonstrated that more than 40% of our EoE patients had a 207 
caesarean section. As such, the rate of caesarean section in our population is consistent with 208 
nation-wide rates. 209 
     Parents affected by chronic diseases often fear of transmitting the disease to their children. 210 
Our data show that almost half of the EoE patients were concerned that the offspring might 211 
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inherit the disease. This fear is justified, as the risk for first-degree relatives to be affected with 212 
EoE is about 2.3%.12 However, the environmental exposures increase the rate of EoE 213 
development to a much greater extent than genetic background.12 Furthermore, the risk for 214 
transmitting EoE from father to the offspring is at least twice as likely as that from mother to 215 
the offspring. Therefore, we have no reasons to discourage female EoE patients from having 216 
children based on the increased risk of disease inheritance alone. 217 
     Our study has several limitations. Relatively small number of patients was examined. 218 
However, since the prevalence of EoE is three-fold lower in female than in male patients1, it is 219 
difficult to study female patients that are of childbearing age and experienced pregnancy. 220 
Despite the low number, our study represents the largest number of pregnant EoE patients ever 221 
examined. Given the retrospective nature of the study, symptoms were assessed using a non-222 
validated instrument. We did not collect the age when the women experienced pregnancy. 223 
However, the mean age in our population was not much higher than the mean age of having 224 
children in average population in Switzerland (32 years). In addition, given that only three 225 
patients underwent esophagogastroduodenoscopy for emergency reasons, we could not 226 
examine the relationship between symptom severity and biologic findings. Nevertheless, given 227 
the clinical need and almost complete absence of literature on course of pregnancy in patients 228 
with EoE, these data might be useful for management of these patients.  229 
     Based on our analysis and on practical experience, we provide the following four 230 
clinical suggestions: 1.) Female EoE patients considering pregnancy should be informed that to 231 
date no increased maternal and fetal risk was observed in pregnant EoE patients on and off 232 
EoE-specific medication; 2.) In patients having inactive disease at the beginning of a pregnancy, 233 
a cessation of the treatment may be considered, provided that the patients undergo regular 234 
monitoring of EoE during pregnancy; 3.) In patients with active disease at the beginning of the 235 
pregnancy the treatment should be continued and 4). After delivery, patients having had an 236 
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improvement in symptoms during pregnancy must be advised to pay attention to a worsening 237 
of symptoms. 238 
      In conclusion, our analysis indicates that clinical course of EoE appears to be favorable 239 
in pregnancy. Use of EoE-specific medications during pregnancy appears to be safe, as we 240 
could not detect a higher rate of pregnancy-related complications in patients having an EoE-241 
specific therapy.  242 
 243 
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